On Wednesday, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported second-quarter 2024 sales of $4.16 billion, beating the consensus of $4.06 billion. Revenues increased 7% year-over-year and 11% on constant currency, mainly due to higher revenues from generic products in all segments and Austedo in the U.S. and International Markets segments. Also Read: FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse. The company’s Generics business grew across all regions – it increased in local currency terms by 16% in the U.S., 8% in Europe, and 22% in International Markets, compared to ...